Literature DB >> 31790278

Serpina3n: Potential drug and challenges, mini review.

Mehwish Saba Aslam1, Liudi Yuan1.   

Abstract

Serpina3n is a secretory serine protease inhibitor belonging to clade "a" exhibiting unique structural and physiological characteristics, playing significant roles ranging from complement cascade, apoptosis, wound healing to Alzheimer by inhibiting a wide range of proteases. Recently studies have reported its significant roles during various pathologies. Although its full range of potential applications are yet to reveal, its reported implications particularly in CNS insults are making it potential therapeutical approach. Here we aim to draw together the literature shedding light on the potential therapeutical applications of Serpina3n/SERPINA3 in various diseases and a brief comparison between murine Serpina3n and its human ortholog SERPINA3 (α1-antichymotrypsin) accounting their biological roles and significance.

Entities:  

Keywords:  Ischaemia; controlled release; expression; immune response; prodrug; skin; stroke therapy; targeting

Year:  2019        PMID: 31790278     DOI: 10.1080/1061186X.2019.1693576

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  9 in total

1.  Inflammatory resolution and vascular barrier restoration after retinal ischemia reperfusion injury.

Authors:  Steven F Abcouwer; Sumathi Shanmugam; Arivalagan Muthusamy; Cheng-Mao Lin; Dejuan Kong; Heather Hager; Xuwen Liu; David A Antonetti
Journal:  J Neuroinflammation       Date:  2021-08-26       Impact factor: 8.322

2.  Therapeutical Significance of Serpina3n Subsequent Cerebral Ischemia via Cytotoxic Granzyme B Inactivation.

Authors:  Mehwish Saba Aslam; Mobeena Saba Aslam; Komal Saba Aslam; Asia Iqbal; Liudi Yuan
Journal:  Biomed Res Int       Date:  2022-05-29       Impact factor: 3.246

3.  A Potential Role for SerpinA3N in Acetaminophen-Induced Hepatotoxicity.

Authors:  Melanie Tran; Jianguo Wu; Li Wang; Dong-Ju Shin
Journal:  Mol Pharmacol       Date:  2021-01-12       Impact factor: 4.436

4.  CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS.

Authors:  Nicolás Fissolo; Clara Matute-Blanch; Mohamoud Osman; Carme Costa; Rucsanda Pinteac; Berta Miró; Alex Sanchez; Verónica Brito; Irena Dujmovic; Margarete Voortman; Michael Khalil; Eva Borràs; Eduard Sabidó; Shohreh Issazadeh-Navikas; Xavier Montalban; Manuel Comabella Lopez
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-01-12

5.  Clinicopathologic and Transcriptomic Analysis of Radiation-Induced Lung Injury in Nonhuman Primates.

Authors:  Priyanka Thakur; Ryne DeBo; Gregory O Dugan; J Daniel Bourland; Kris T Michalson; John D Olson; Thomas C Register; Nancy D Kock; J Mark Cline
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-04-20       Impact factor: 8.013

Review 6.  Granzyme B in Inflammatory Diseases: Apoptosis, Inflammation, Extracellular Matrix Remodeling, Epithelial-to-Mesenchymal Transition and Fibrosis.

Authors:  Francesca Velotti; Ilaria Barchetta; Flavia Agata Cimini; Maria Gisella Cavallo
Journal:  Front Immunol       Date:  2020-11-11       Impact factor: 7.561

7.  Alendronate Enhances Functional Recovery after Spinal Cord Injury.

Authors:  Yuna Choi; Taekyun Shin
Journal:  Exp Neurobiol       Date:  2022-02-28       Impact factor: 3.261

Review 8.  Potential role of extracellular granzyme B in wet age-related macular degeneration and fuchs endothelial corneal dystrophy.

Authors:  Eden Dubchak; Gideon Obasanmi; Matthew R Zeglinski; David J Granville; Sonia N Yeung; Joanne A Matsubara
Journal:  Front Pharmacol       Date:  2022-09-20       Impact factor: 5.988

9.  Molecular Examination of Differentially Expressed Genes in the Brains of Experimental Autoimmune Encephalomyelitis Mice Post Herceptin Treatment.

Authors:  Mena Al-Ani; Noha Mousaad Elemam; Ibrahim Y Hachim; Tom K Raju; Jibran Sualeh Muhammad; Mahmood Y Hachim; Riyad Bendardaf; Azzam A Maghazachi
Journal:  J Inflamm Res       Date:  2021-06-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.